TearLab Osmolarity System

TearLab (NASDAQ:TEAR; TSX:TLB) has reported third quarter net revenues of $1.2-million, an increase of 264% from $333,000 for the same period in 2011, and up 69% sequentially from $716,000 in the second quarter this year.

TearLab Osmolarity System

Growing doctor interest in our technology and the significant role that it can play in the objective diagnoses and management of dry eye disease drove our strong revenue performance in what is historically a seasonally weaker third quarter in the eye care industry. A total of 92 orders for TearLab systems were booked in the period.  Of those, 77 were through the company’s access programs, 6 were direct purchases and 9 were purchased outside of the U.S.


Leave a comment

May 29, 2013 · 5:20 pm

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s